Aegerion Sets IPO Terms

Aegerion Pharmaceuticals Inc., a Bridgewater, N.J.-based drug company focused on cardiovascular and metabolic disease, set its proposed IPO terms to five million common shares being offered at between $12 and $14 per share. It plans to trade on the Nasdaq under ticker symbol AEGR, with Lehman Brothers serving as lead underwriter. The company raised around $22.5 million in Series A funding in 2005 from firms like Alta Partners, Advent International, Index Ventures, MVM Life Science Partners and Scheer & Co. www.aegerion.com